ClinicalTrials.gov
ClinicalTrials.gov Menu

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01523587
Recruitment Status : Completed
First Posted : February 1, 2012
Results First Posted : November 21, 2014
Last Update Posted : January 8, 2018
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy. The primary objective of this trial is to compare the efficacy of BIBW 2992 to erlotinib as second-line treatment in this group of patients.

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: afatinib Drug: erlotinib Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 795 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy
Actual Study Start Date : March 5, 2012
Actual Primary Completion Date : August 27, 2013
Actual Study Completion Date : November 29, 2017

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Afatinib
Patients receive afatinib tablets once daily
Drug: afatinib
Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
Active Comparator: Erlotinib
Patients receive erlotinib tablets once daily
Drug: erlotinib
erlotinib taken once daily



Primary Outcome Measures :
  1. Progression-free Survival, Based on Central Independent Review as Determined by RECIST 1.1 [ Time Frame: First treatment administration up until cut off date of 7th October 2013 (up to 78 weeks). ]
    The primary endpoint of this study was Progression Free Survival (PFS), as determined by central independent review according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. PFS was defined as the time from randomisation to disease progression (or death if the patient died before progression).


Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: From randomisation until 632 deaths ]

    The primary analysis of Overall Survival (OS) will be conducted after 632 deaths have occured.

    Overall Survival is defined as the time from randomisation to death.


  2. Objective Response According to RECIST 1.1 [ Time Frame: First treatment administration until cut off date of 7th October 2013 (up to 78 weeks). ]
    Objective response as defined by RECIST 1.1 as either complete response (CR) or partial response (PR).

  3. Disease Control According to RECIST 1.1 [ Time Frame: First treatment administration until cut off date of 7th October 2013 (up to 78 weeks). ]
    Disease control (defined as CR, PR or Stable Disease (SD)) according to RECIST 1.1.

  4. Tumour Shrinkage [ Time Frame: First treatment administration until cut off date of 7th October 2013 (up to 78 weeks). ]

    Maximum percentage decrease from baseline in the sum of target lesion diameters following independent review.

    The change in the size (i.e. the sum of diameters (SOD)) of target lesions from baseline was derived. Tumour shrinkage for each patient was measured (based on Independent Radiologic Review (IRR)) as the minimum SOD of target lesions after randomisation.

    A negative percentage indicates decrease from baseline; positive numbers indicate an increase of tumour size. The mean maximum decrease from baseline of +5 and +9.4 reflect an average increase in tumour size.


  5. Status Change in Cough, Dyspnoea and Pain Related Items Over Time in Health Related Quality of Life Questionnaire [ Time Frame: First treatment administration up to 28 days after the last intake of study medication. ]

    Health-related quality of life (HRQoL) was measured with the following multi-dimensional questionnaires: the EORTC QLQ-C30 questionnaire and its lung cancer specific supplementary module EORTC QLQ-LC13 and the EQ-5D health status self-assessment questionnaire. The questionnaires were assessed at the first visit of each treatment course, at EOT and follow up prior to clinical assessment. The results displayed show improvement in the relevant criteria.

    For each of the summary scales and items measuring cough, dyspnoea and pain, the two treatment arms were compared in terms of: The proportion of patients that were improved: Change in cough; dyspnoea and pain scores over time.


  6. Summary of Time to Deterioration in Coughing, Dyspnoea and Pain. [ Time Frame: First treatment administration up to 28 days after the last intake of study medication. ]
    Health-related quality of life (HRQoL) was measured with the following multi-dimensional questionnaires: the EORTC QLQ-C30. The questionnaires were assessed at the first visit of each treatment course. For each of the summary scales and items measuring cough, dyspnoea and pain, the two treatment arms were compared in terms of: Time to deterioration.

  7. Change in Score Over Time in Coughing,Dyspnoea and Pain [ Time Frame: First treatment administration up to 28 days after last intake of study medication ]

    Health related quality of life (HRQoL) was measured with the following multi dimensional questionnaires: the EORTC QLQ-C30. The questionnaires were assessed at the first visit of each treatment course. For each of the summary scales and items measuring cough, dyspnoea and pain, the two treatment arms were compared in terms of change in score over time, adjusted for baseline score and race.

    Questionnaires have items relating to Cough, Dyspnoea and Pain. Overall Scores are transformed to a standardised scale of 0 to 100 with the larger value indicating a worse outcome. A change of (+/-) 10 points is considered to be relevant.

    The change in cough, dyspnea and pain will be assessed using a mixed effects growth curve model with the average profile over time for each endpoint described by a piecewise linear model (presented as post baseline in data table).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Diagnosis of advanced stage NSCLC squamous histology.
  2. Platinum-based doublet chemotherapy as 1st line treatment of Stage IIIB/IV NSCLC.
  3. Eligible to receive 2nd line therapy in the opinion of the investigator.
  4. Measurable disease according to RECIST 1.1.
  5. Adequate Performance Status.
  6. Availability of tumour tissue material for correlative studies. Archived tumour tissue is acceptable.
  7. Adequate organ function.
  8. Age = 18 years and above.
  9. Written informed consent that is consistent with ICH-GCP guidelines.

Exclusion criteria:

  1. Prior treatment with EGFR directed small molecules or antibodies.
  2. Radiotherapy within 4 weeks prior to randomization.
  3. Active brain metastases .
  4. Any other current malignancy or malignancy diagnosed within the past three (3) years (other than basal-cell carcinoma of the skin, in situ cervical cancer, in situ prostate cancer).
  5. Known pre-existing interstitial lung disease.
  6. Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom
  7. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
  8. Women of child-bearing potential and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.
  9. Female patients of childbearing potential (see Section 4.2.3.3) who:

    1. are nursing or
    2. are pregnant or
    3. are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
  10. Active hepatitis B infection (defined as presence of Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.
  11. Known or suspected active drug or alcohol abuse in the opinion of the investigator.
  12. Any contraindications for therapy with afatinib or erlotinib.
  13. Known hypersensitivity to erlotinib, afatinib or the excipients of any of the trial drugs.
  14. Major surgery within 4 weeks of starting study treatment.
  15. Prior participation in an afatinib clinical study, even if not assigned to afatinib.
  16. Use of any investigational drug within 4 weeks of randomisation (unless a longer time period is required by local regulations or by the guidelines for the investigational product).
  17. Patients without Progression of their lung cancer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01523587


  Hide Study Locations
Locations
United States, Arizona
Ironwood Cancer and Research Centers
Chandler, Arizona, United States, 85224
United States, California
University of California
La Jolla, California, United States, 92093
Sutter Medical Group
Sacramento, California, United States, 95816
United States, Florida
Boca Raton Reginl Hospital-Lynn Cancer Institute
Boca Raton, Florida, United States, 33486
Memorial Healthcare System
Hollywood, Florida, United States, 22021
Cancer Care of North Florida, PA
Lake City, Florida, United States, 32024
United States, Illinois
Illinois Cancer Specialists
Niles, Illinois, United States, 60714
Orchard Healthcare Research Inc
Skokie, Illinois, United States, 60076
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Louisiana
West Jefferson General Hospital and Cancer Clinic
Marrero, Louisiana, United States, 70072
United States, Massachusetts
Lahey Clinic
Burlington, Massachusetts, United States, 01805
Commonwealth Hematology-Oncology, PC
Lawrence, Massachusetts, United States, 01841
United States, Michigan
Karmanos Cancer Center at the Detroit Medical Center
Detroit, Michigan, United States, 48201
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Montana
Billings Clinic Cancer Center
Billings, Montana, United States, 59101
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10461
Montefiore Medical Center
Bronx, New York, United States, 10467
Queens Medical Associates
Fresh Meadows, New York, United States, 11366
SUNY Upstate Medical University
Syracuse, New York, United States, 13210
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43201
Mid Ohio Oncology/Hematology, Inc
Columbus, Ohio, United States, 43219
United States, Oregon
Kaiser Permanente Northwest
Portland, Oregon, United States, 97227
United States, Pennsylvania
Oncology Hematology Associates of Norhtern Pennsylvania, PC
DuBois, Pennsylvania, United States, 15801
Kimmel Cancer Center
Philadelphia, Pennsylvania, United States, 19107
Temple University Cancer Center
Philadelphia, Pennsylvania, United States, 19140
United States, South Carolina
Spartanburg Regional Medical Center
Spartanburg, South Carolina, United States, 29303
United States, Tennessee
Cancer Center of Cookeville Regional Medical Center
Cookeville, Tennessee, United States, 38501
United States, Texas
Paris Cancer Center (PCC), Texas Oncology
Paris, Texas, United States, 75460
Cancer Therapy and Research at UTHSCSA
San Antonio, Texas, United States, 78229
United States, Vermont
Fletcher Allen Health Care
Burlington, Vermont, United States, 05401
United States, Virginia
Blue Ridge Cancer Care
Christiansburg, Virginia, United States, 24382
Virginia Oncology Associates
Norfolk, Virginia, United States, 23502
Argentina
Instituto Medico Especializado Alexander Fleming
Ciudad Autonoma de Bs As, Argentina, C1426ANZ
Instituto Oncologico de Cordoba
Cordoba, Argentina, X5000HXL
Clínica Colombo S.A.
Cordoba, Argentina, X5002AOQ
Centro Oncologico de Rosario
Rosario, Argentina, S2000KZE
Centro Oncologico CAIPO
San Miguel de Tucuman, Argentina, T4000GTB
Austria
Medical University of Innsbruck
Innsbruck, Austria, 6020
LKH Leoben
Leoben, Austria, 8700
AKH d. Stadt Linz, Pulmologie
Linz, Austria, 4020
SMZ Baumgartner Hoehe Otto Wagner Spital
Wien, Austria, 1140
Canada, British Columbia
BC Cancer Agency - Fraser Valley Centre
Surrey, British Columbia, Canada, V3V 1Z2
Canada, Ontario
Kingston General Hospital
Kingston, Ontario, Canada, K7L 5P9
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Canada, Quebec
Royal Victoria Hospital
Montreal, Quebec, Canada, H3A 1A1
Montreal General Hospital - McGill University Health Centre
Montreal, Quebec, Canada, H3G 1A4
Chile
Centro Oncologico Antofagasta
Antofagasta, Chile, 1720421
Instituto de Terapias Oncologicas Providencia
Providencia, Santiago, Chile, 7501088
Centro Internacional de Estudios Clinicos - CIEC
Recoleta, Santiago De Chile, Chile, 8420383
Orlandi Oncologia
Vitacura, Chile, 7630457
China
Beijing Cancer Hospital
Beijing, China, 100036
Beijing Hospital
Beijing, China, 100730
First Hospital of Jilin University
Changchun, China, 130021
Xiangya Hospital, Central South University
Changsha, China, 410008
Sun Yat-Sen University Cancer Center
Guangzhou, China, 510060
the 81th Hospital of PLA
Nanjing, China, 210002
Jiangsu Cancer Hospital
Nanjing, China, 210009
Shanghai Chest Hospital
Shanghai, China, 200030
Shanghai Pulmonary Hospital
Shanghai, China, 200433
Denmark
Herlev Hospital
Herlev, Denmark, 2730
Næstved Sygehus
Næstved, Denmark, 4700
Odense Universitetshospital
Odense C, Denmark, 5000
France
HOP d'Angers
Angers Cedex 9, France, 49 933
INS Bergonié
Bordeaux, France, 33076
HOP Côte de Nacre
Caen, France, 14033
HOP de Chauny
Chauny, France, 02303
HOP Gabriel-Montpied
Clermont Ferrand, France, 63003
HOP de Creteil, Pneumo, Creteil
Creteil, France, 94010
HOP Le Mans
Le Mans, France, 72037
CTR Oscar Lambret, Cancéro, Lille
Lille, France, 59020
HOP Calmette
Lille, France, 59037
HOP Nord
Marseille Cedex 20, France, 13915
INS Paoli-Calmettes
Marseille, France, 13273
HOP de Mulhouse, Onco, Mulhouse
Mulhouse, France, 68070
HOP Cochin
Paris, France, 75014
HOP Val de Grâce, Onco, Paris
Paris, France, 75230
INS Jean Godinot, Onco, Reims
Reims, France, 51056
HOP de Rennes, Pneumo, Rennes
Rennes, France, 35033
HOP Saint Quentin, Onco, Saint Quentin
Saint Quentin, France, 02321
HOP Civil
Strasbourg, France, 67091
HOP Foch
Suresnes, France, 92151
INS Gustave Roussy
Villejuif, France, 94805
Germany
Zentralklinik Bad Berka GmbH
Bad Berka, Germany, 99437
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
Essen, Germany, 45147
Klinikum Esslingen GmbH
Esslingen, Germany, 73730
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany, 60590
Universitätsklinikum Freiburg
Freiburg, Germany, 79106
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany, 20246
Lungenklinik Hemer
Hemer, Germany, 58675
Klinikum Mannheim GmbH
Mannheim, Germany, 68167
Universitätsklinikum Münster
Münster, Germany, 48149
Mathias-Spital Rheine
Rheine, Germany, 48431
Greece
"Hippokratio" Hospital of Athens, 2nd Internal Medicine Clin
Athens, Greece, 11527
General Hospital of Chest Diseases Sotiria
Athens, Greece, 11527
University General Hospital of Heraklion
Heraklion, Greece, 71110
University Hospital of Larisa, Oncology Clinic
Larisa, Greece, 41110
General Hospital of Larissa
Larisa, Greece, 41221
Metropolitan Hospital, Oncology Clinic
Neo Faliro, Athens, Greece, 18547
General Hospital "G. Papageorgiou"
Thessaloniki, Greece, 56429
Hungary
National Koranyi TBC and Pulm. Internal Med. Clinic
Budapest, Hungary, 1121
Semmelweis University, Dept. Pulmonology
Budapest, Hungary, 1125
Institute of Chest Diseases Csongrad County,Dpt. Pulmonology
Deszk, Hungary, 6772
Pulmonology Institute of Veszprem County, Farkasgyepu
Farkasgyepü, Hungary, 8582
Aladar Petz County Teaching Hospital, Dept. Pulmonology
Györ, Hungary, 9023
Lung Hospital of Matra, Dept. Pulmonology
Matrahaza, Hungary, 3233
Josa Andras Korhaz, Nyiregyhaza
Nyiregyhaza, Hungary, 4400
University of Pecs, 1st internal Med. Dept., Pulmonology
Pecs, Hungary, 7623
Pest County Lung Hospital, Department No. 3
Törökbalint, Hungary, 2045
India
Vikram Hospital
Bangalore, India, 560052
V S Hospital
Chennai, India, 600031
Dr. Kamakshi Memorial Hospital
Chennai, India, 600100
Sri Ramachandra Medical College & Research Institute
Chennai, India, 600116
M.S. Patel Cancer Hospital
Karamsad, India, 388325
B. P .Poddar Hospital & Medical Research Ltd.
Kolkata, West Bengal, India, 700053
Tata Memorial Hospital
Mumbai, India, 400012
Ruby Hall Clinic
Pune, India, 411001
Ireland
St James's Hospital
Dublin 8, Ireland, Dublin
Italy
P.O. Bellaria IRCCS Istituto delle scienze Neurologiche di Bologna
Bologna, Italy, 40139
ASST di Cremona
Cremona, Italy, 26100
Spedali Riuniti di Livorno
Livorno, Italy, 57100
Istituto Nazionale Tumori Fondazione Pascale
Napoli, Italy, 80131
Istituto Oncologico Veneto IRCCS
Padova, Italy, 35128
Azienda Ospedaliera di Parma
Parma, Italy, 43100
Azienda Ospedaliera Universitaria Pisana
Pisa, Italy, 56126
Istituto Clinico Humanitas
Rozzano (MI), Italy, 20089
Ospedale San Vincenzo
Taormina (ME), Italy, 98039
Ospedale Molinette, AO Città della Salute e della
Torino, Italy, 10126
A. O. S. Maria della Misericordia
Udine, Italy, 33100
Korea, Republic of
Chungbuk National University Hospital
Cheongju, Korea, Republic of, 361-711
Gachon University Gil Medical Center
Incheon, Korea, Republic of, 405-760
Gyeongsang National University Hospital
Jinju, Korea, Republic of, 660-702
Seoul National University Bundang Hospital
Seongnam, Korea, Republic of, 13620
Samsung Medical Center
Seoul, Korea, Republic of, 130-710
The Catholic University of Korea, Seoul St.Mary's Hospital
Seoul, Korea, Republic of, 137-701
Asan Medical Center
Seoul, Korea, Republic of, 138-736
The Catholic University of Korea, St.Vincent's Hospital
Suwon, Korea, Republic of, 442-723
Ulsan University Hospital
Ulsan, Korea, Republic of, 682-714
Mexico
Instituto Nacional de Cancerologia
Mexico, Mexico, 14080
Hospital y Clínica OCA S. A. de C. V.
Monterrey, Mexico, 64000
Centro Hemato-Oncologico Privado de Toluca S.A. de C.V.
Toluca, Mexico, 50080
Netherlands
Jeroen Bosch Ziekenhuis-Hertogenbosch
's-HERTOGENBOSCH, Netherlands, 5223 GZ
Rijnstate Hospital
Arnhem, Netherlands, 6815 AD
Amphia Ziekenhuis
Breda, Netherlands, 4818 CK
Catharina Ziekenhuis
Eindhoven, Netherlands, 5623 EJ
Medisch Ethische Commissie Academisch Ziekenhuis Maastricht
Maastricht, Netherlands, 6229 HX
St. Antonius ziekenhuis, locatie Nieuwegein
Nieuwegein, Netherlands, 3435 CM
Erasmus Medisch Centrum
Rotterdam, Netherlands, 3015 CD
Portugal
CHUC - Centro Hospitalar e Universitário de Coimbra, EPE
Coimbra, Portugal, 3041-801
CHLN, EPE - Hospital de Santa Maria
Lisboa, Portugal, 1064-035
IPO Lisboa Francisco Gentil, EPE
Lisboa, Portugal, 1099-023
IPO Porto Francisco Gentil, EPE, Oncology Dep.
Porto, Portugal, 4200-072
Centro Hospitalar São João,EPE
Porto, Portugal, 4200-319
Centro Hospitalar de Vila Nova de Gaia
Vila Nova de Gaia, Portugal, 4434-502
Singapore
National Cancer Centre
Singapore, Singapore, 169610
Johns Hopkins Singapore International Medical Centre
Singapore, Singapore, 308433
Spain
Hospital A Coruña
A Coruña, Spain, 15006
Hospital Vall d'Hebron
Barcelona, Spain, 08035
Hospital Santa Creu i Sant Pau
Barcelona, Spain, 08041
Hospital Clínico San Carlos
Madrid, Spain, 28040
Hospital La Paz
Madrid, Spain, 28046
Hospital Regional Universitario de Málaga
Malaga, Spain, 29010
Hospital Virgen de la Victoria
Malaga, Spain, 29010
Hospital Clínico de Valencia
Valencia, Spain, 46010
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Spain, 50009
Taiwan
Chang Gung Memorial Hospital Chiayi
Chiayi, Taiwan, 613
Buddhist Tzu Chi General Hospital
Chiayi, Taiwan, 622
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung, Taiwan, 833
China Medical University Hospital
Taichung, Taiwan, 404
Taichung Veterans General Hospital
Taichung, Taiwan, 407
National Taiwan University Hospital
Taipei, Taiwan, 100
Koo Foundation Sun Yet-Sen Cancer Center
Taipei, Taiwan, 112
Taipe Veterans General Hospital
Taipei, Taiwan, 112
Chang Gung Memorial Hospital(TaoYuan)
Taoyuan, Taiwan, 330
Turkey
Akdeniz Universitesi Tip Fakultesi
Antalya, Turkey, 07070
Uludag Universitesi Tip Fakultesi, Bursa
Bursa, Turkey, 16045
Dicle Universitesi Tip Fakultesi
Diyarbakir, Turkey
Gaziantep Univ. Tip Fakultesi Tibbi Onkoloji Bilim Dali
Gaziantep, Turkey, 27310
Kartal Egitim Ve Arastirma Hastanesi
Istanbul, Turkey
Yedikule Gog. Hst. EAH
Istanbul, Turkey
Ege Universitesi Tip Fakultesi Tibbi Onkoloji Bilim Dali
Izmir, Turkey, 35100
Dr.Suat Seren EAH
Izmir, Turkey, 35120
United Kingdom
Queen Elizabeth Hospital
Birmingham, United Kingdom, B15 2TH
Royal Devon and Exeter Hospital
Exeter, United Kingdom, EX2 5DW
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom, G12 0YN
Harrogate District Hospital
Harrogate, United Kingdom, HG2 7SX
Royal Free Hospital
London, United Kingdom, NW3 2QG
The Royal Marsden Hospital
London, United Kingdom, SW3 6JJ
Maidstone Hospital, Kent Oncology Centre
Maidstone, United Kingdom, ME16 9QQ
Nottingham City Hospital
Nottingham, United Kingdom, NG5 1PB
Scarborough Hospital
Scarborough, United Kingdom, YO12 6QL
The Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01523587     History of Changes
Other Study ID Numbers: 1200.125
2011-002380-24 ( EudraCT Number )
First Posted: February 1, 2012    Key Record Dates
Results First Posted: November 21, 2014
Last Update Posted: January 8, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action